BR112013028914A2 - antagonistas de receptores de integrina e seus métodos de uso - Google Patents
antagonistas de receptores de integrina e seus métodos de usoInfo
- Publication number
- BR112013028914A2 BR112013028914A2 BR112013028914A BR112013028914A BR112013028914A2 BR 112013028914 A2 BR112013028914 A2 BR 112013028914A2 BR 112013028914 A BR112013028914 A BR 112013028914A BR 112013028914 A BR112013028914 A BR 112013028914A BR 112013028914 A2 BR112013028914 A2 BR 112013028914A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- integrin
- receptor antagonists
- cooh
- inhibition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
- C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
- A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
Abstract
antagonistas de receptores de integrina e seus métodos de uso compostos que compreendem r-g-ácido cistéico (iso é, r-g-nh-ch(ch~ 2~-so~ 3~h)cooh ou arg-gly-nh-ch(ch~ 2~-so~ 3~h)cooh) e derivados dos mesmos, incluindo sais farmaceuticamente aceitáveis, hidratos, estereoisômeros, multímeros, formas cíclicas, formas lineares, conjugadas de fármacos, pró-fármacos e seus derivados. são também divulgados métodos para a produção e utilização de tais compostos incluindo métodos para a inibição de integrinas incluindo, mas não necessariamente limitados a <244>~ 5~ß~ 1~-integrina, <244>~ v~ß~ 3~-integrina e <244>~ v~ß~ 5~-integrina, inibição de adesão celular a sítios de ligação de rgd, prevenção ou tratamento viral ou de outras infecções microbianas, inibição da angiogênese em tumores, tecido da retina ou outros tecidos ou fornecimento de outros agentes de diagnóstico ou terapêuticos aos ditos de ligação a rgd em indivíduos humanos ou animais.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161484194P | 2011-05-09 | 2011-05-09 | |
US61/484.194 | 2011-05-09 | ||
US201161486195P | 2011-05-13 | 2011-05-13 | |
US61/486.195 | 2011-05-13 | ||
US201261643118P | 2012-05-04 | 2012-05-04 | |
US61/643.118 | 2012-05-04 | ||
PCT/US2012/037177 WO2012154894A2 (en) | 2011-05-09 | 2012-05-09 | Integrin receptor antagonists and their methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112013028914A2 true BR112013028914A2 (pt) | 2017-11-07 |
BR112013028914B1 BR112013028914B1 (pt) | 2022-02-15 |
Family
ID=47139985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013028914-7A BR112013028914B1 (pt) | 2011-05-09 | 2012-05-09 | Uso de um peptídeo inibidor de integrina que consiste em glicinil-arginil-glicinil-cisteico (ácido)-treonil-prolina-cooh para tratar edema macular |
Country Status (15)
Country | Link |
---|---|
US (2) | US9896480B2 (pt) |
EP (2) | EP3243530B1 (pt) |
JP (4) | JP6106159B2 (pt) |
KR (2) | KR102019970B1 (pt) |
CN (1) | CN104080467B (pt) |
AU (5) | AU2012253511A1 (pt) |
BR (1) | BR112013028914B1 (pt) |
CA (1) | CA2835214C (pt) |
ES (1) | ES2820855T3 (pt) |
HK (1) | HK1202449A1 (pt) |
IL (1) | IL229299A0 (pt) |
MX (1) | MX2013012953A (pt) |
RU (1) | RU2721907C2 (pt) |
WO (1) | WO2012154894A2 (pt) |
ZA (1) | ZA201308325B (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX346362B (es) | 2009-11-10 | 2017-03-15 | Allegro Pharmaceuticals Inc * | Composiciones y metodos para inhibir la adhesion celular o dirigir agentes de diagnostico o terapeuticos a sitios de enlace rgd. |
US11673914B2 (en) | 2009-11-10 | 2023-06-13 | Allegro Pharmaceuticals, LLC | Peptide therapies for reduction of macular thickening |
ES2820855T3 (es) | 2011-05-09 | 2021-04-22 | Allegro Pharmaceuticals Llc | Antagonistas del receptor de integrina y sus métodos de uso |
US8901144B2 (en) | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
KR102216091B1 (ko) | 2013-02-07 | 2021-02-16 | 사이플루어 라이프 사이언시즈, 인크 | 플루오르화 인테그린 길항제 |
AU2016219906B2 (en) | 2015-02-19 | 2020-10-01 | Scifluor Life Sciences, Inc. | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
KR20180088713A (ko) * | 2015-12-04 | 2018-08-06 | 얀센 바이오테크 인코포레이티드 | 전구 세포를 사용한 망막 변성의 치료 |
CN105837666A (zh) * | 2015-12-30 | 2016-08-10 | 田梗 | 一种用于诊断糖尿病性视网膜病的蛋白质 |
US11045435B2 (en) * | 2016-09-29 | 2021-06-29 | Naturewise Biotech & Medicals Corporation | Methods for treating ocular diseases |
JP7179010B2 (ja) * | 2016-12-12 | 2022-11-28 | ソルボンヌ・ユニヴェルシテ | 血管新生阻害剤としてのc型レクチンであるレベセチン |
AU2018210241A1 (en) * | 2017-01-19 | 2019-08-22 | Allegro Pharmaceuticals, LLC. | Therapeutic and neuroprotective peptides |
EP3642219A4 (en) * | 2017-06-19 | 2021-06-09 | Allegro Pharmaceuticals, LLC | PEPTIDE COMPOSITIONS AND RELATED PROCEDURES |
CN111658647A (zh) * | 2019-03-08 | 2020-09-15 | 首都医科大学宣武医院 | 沙利度胺及其衍生物的用途 |
CA3145870A1 (en) * | 2019-07-26 | 2021-02-04 | Hampar L. Karageozian | Peptides for treating non-exudative macular degeneration and other disorders of the eye |
CN115605215A (zh) * | 2020-03-06 | 2023-01-13 | 急速制药有限责任公司(Us) | 改善或减轻线粒体功能损伤的治疗 |
WO2022183360A1 (en) * | 2021-03-02 | 2022-09-09 | Tsao Yeou Ping | Short synthetic peptide and their uses for treating dry eye disease |
CN116059312A (zh) * | 2021-07-23 | 2023-05-05 | 百奥泰生物制药股份有限公司 | 整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用 |
CN117771376B (zh) * | 2024-02-26 | 2024-05-03 | 四川大学华西第二医院 | 一类化合物在注意缺陷与多动障碍中的应用及产品 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4589881A (en) | 1982-08-04 | 1986-05-20 | La Jolla Cancer Research Foundation | Polypeptide |
US4578079A (en) | 1982-08-04 | 1986-03-25 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4661111A (en) | 1982-08-04 | 1987-04-28 | La Jolla Cancer Research Foundation | Polypeptide |
US4614517A (en) | 1982-08-04 | 1986-09-30 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4517686A (en) | 1982-08-04 | 1985-05-21 | La Jolla Cancer Research Foundation | Polypeptide |
US5635477A (en) * | 1991-09-30 | 1997-06-03 | The Dupont Merck Pharmaceutical Company | Cyclic compounds useful as inhibitors of platelet glycoprotein IIB/IIIA |
CA2159070A1 (en) | 1993-03-29 | 1994-10-13 | William Frank Degrado | Cyclic compounds useful as inhibitors of platelet glycoprotein iib/iiia |
US6346604B1 (en) | 1995-10-31 | 2002-02-12 | Takeda Chemical Industries, Inc. | Method for controlling conformation of cyclopentapeptide |
AU2958195A (en) | 1994-06-29 | 1996-01-25 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin |
JPH08119991A (ja) | 1994-10-24 | 1996-05-14 | Otsuka Pharmaceut Factory Inc | ペプチド誘導体及びil−1産生抑制剤 |
US6551574B2 (en) * | 1995-06-07 | 2003-04-22 | Rhomed Incorporated | Tuftsin metallopeptide analogs and uses thereof |
US6610292B2 (en) | 1995-11-22 | 2003-08-26 | Ista Pharmaceuticals, Inc. | Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders |
PT951295E (pt) | 1996-05-31 | 2010-07-29 | Scripps Research Inst | COMPOSIÃES PARA UTILIZAÃO NA INIBIÃO DE ANGIOGéNESE MEDIADA POR ALFA-V-BETA3 |
US6331285B1 (en) | 1996-06-05 | 2001-12-18 | Palatin Technologies, Inc. | Structurally determined cyclic metallo-constructs and applications |
US20030170250A1 (en) | 1998-03-23 | 2003-09-11 | Ezrin Alan M. | Local delivery of long lasting therapeutic agents |
WO1999063084A1 (fr) | 1998-05-29 | 1999-12-09 | St. Marianna University School Of Medicine | Sequences de recepteurs d'antigenes de lymphocytes t specifiques d'arthrosis deformans |
US7030211B1 (en) | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
EP1147214B1 (en) | 1999-01-13 | 2011-01-05 | The Research Foundation Of State University Of New York | A novel method for designing protein kinase inhibitors |
US7070936B1 (en) | 1999-01-13 | 2006-07-04 | The Research Foundation Of State University Of New York | Method for designing protein kinase inhibitors |
US20040072315A1 (en) * | 2001-02-05 | 2004-04-15 | Xinjie Lu | Integrin-binding chimeras |
WO2002067972A1 (en) * | 2001-02-28 | 2002-09-06 | Duke University | Method of inducing vitreous detachment |
JP2002326949A (ja) | 2001-05-02 | 2002-11-15 | Kansai Tlo Kk | 免疫賦活剤 |
US7906102B2 (en) | 2001-10-03 | 2011-03-15 | Vanderbilt University | Ligands to radiation-induced molecules |
AU2002363253A1 (en) | 2001-11-01 | 2003-05-12 | Gpc Biotech Inc. | Endothelial-cell binding peptides for diagnosis and therapy |
US20060029544A1 (en) | 2004-08-06 | 2006-02-09 | The Regents Of The University Of California Office Of Technology Transfer | Receptor-binding cyclic peptides and methods of use |
WO2008134761A2 (en) | 2007-04-30 | 2008-11-06 | Intezyne Technologies, Inc. | Modification of biological targeting groups for the treatment of cancer |
CN101687911A (zh) | 2007-05-16 | 2010-03-31 | 康久化学生物技术公司 | 抗病毒肽的半胱磺酸衍生物 |
MX346362B (es) | 2009-11-10 | 2017-03-15 | Allegro Pharmaceuticals Inc * | Composiciones y metodos para inhibir la adhesion celular o dirigir agentes de diagnostico o terapeuticos a sitios de enlace rgd. |
ES2820855T3 (es) | 2011-05-09 | 2021-04-22 | Allegro Pharmaceuticals Llc | Antagonistas del receptor de integrina y sus métodos de uso |
-
2012
- 2012-05-09 ES ES17159955T patent/ES2820855T3/es active Active
- 2012-05-09 WO PCT/US2012/037177 patent/WO2012154894A2/en active Application Filing
- 2012-05-09 CN CN201280034143.3A patent/CN104080467B/zh active Active
- 2012-05-09 US US13/467,995 patent/US9896480B2/en active Active
- 2012-05-09 EP EP17159955.8A patent/EP3243530B1/en active Active
- 2012-05-09 RU RU2013153152A patent/RU2721907C2/ru active
- 2012-05-09 JP JP2014510451A patent/JP6106159B2/ja active Active
- 2012-05-09 KR KR1020137032421A patent/KR102019970B1/ko active IP Right Grant
- 2012-05-09 AU AU2012253511A patent/AU2012253511A1/en not_active Abandoned
- 2012-05-09 CA CA2835214A patent/CA2835214C/en active Active
- 2012-05-09 KR KR1020197025906A patent/KR102165421B1/ko active IP Right Grant
- 2012-05-09 EP EP12782195.7A patent/EP2707036A4/en not_active Withdrawn
- 2012-05-09 BR BR112013028914-7A patent/BR112013028914B1/pt active IP Right Grant
- 2012-05-09 MX MX2013012953A patent/MX2013012953A/es active IP Right Grant
-
2013
- 2013-11-06 ZA ZA2013/08325A patent/ZA201308325B/en unknown
- 2013-11-07 IL IL229299A patent/IL229299A0/en active IP Right Grant
-
2015
- 2015-03-30 HK HK15103165.6A patent/HK1202449A1/xx unknown
-
2017
- 2017-03-03 JP JP2017040516A patent/JP6383031B2/ja active Active
- 2017-06-21 AU AU2017204193A patent/AU2017204193A1/en not_active Abandoned
-
2018
- 2018-01-10 US US15/867,139 patent/US10590166B2/en active Active
- 2018-08-02 JP JP2018146060A patent/JP6788154B2/ja not_active Revoked
- 2018-11-14 AU AU2018264033A patent/AU2018264033B2/en active Active
-
2020
- 2020-07-31 JP JP2020130450A patent/JP7197199B2/ja active Active
- 2020-10-08 AU AU2020250268A patent/AU2020250268B2/en active Active
-
2023
- 2023-02-10 AU AU2023200742A patent/AU2023200742A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013028914A2 (pt) | antagonistas de receptores de integrina e seus métodos de uso | |
CY1117815T1 (el) | Τοπικο σκευασμα για εναν αναστολεα jak | |
MX2011010859A (es) | Peptidos utiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosmeticas o farmaceuticas. | |
MX2011008616A (es) | Peptidos utiles en el tratamiento y/o cuidado de la piel , mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas. | |
BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
BR112017007662A8 (pt) | Composto, composição farmacêutica e uso de um composto | |
ES2397889A1 (es) | PÉPTIDOS MODULADORES DE PGC-1Alfa. | |
BR112014010105A2 (pt) | aminas de c-28 de derivados de ácido betulínico modificado por c-3 como inibidores de maturação de hiv | |
BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
BR112015001419A8 (pt) | composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
ME02414B (me) | Tretman kronove bolesti lakvinimodom | |
BRPI0812504B8 (pt) | composto para profilaxia ou tratamento de doença ou condição associada a receptor de canabinoides em sujeito mamífero | |
MX2012005222A (es) | Composiciones y metodos para inhibir la adhesion celular o dirigir agentes de diagnostico o terapeuticos a sitios de enlace rgd. | |
EA201291220A1 (ru) | Производные аминопиримидина в качестве модуляторов lrrk2 | |
AU2011274192A8 (en) | Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof | |
BR112013020005A8 (pt) | peptídeo de fórmula geral r1-wn-xm-aa1-aa2-aa3-aa4-aa5-aa6-yp-zq-r2, seus estereoisômeros, misturas dos mesmos e/ou seus sais cosmética ou farmaceuticamente aceitáveis e composição cosmética ou farmacêutica | |
BR112014027117A8 (pt) | Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição | |
MX336881B (es) | Compuestos heterociclicos triciclicos. | |
EA200901423A1 (ru) | Бензимидазолы и содержащие их фармацевтические композиции | |
JP2014050390A5 (pt) | ||
MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
RS54438B1 (en) | PHARMACEUTICAL DOSAGE FORM CONTAINING 6`-FLUORO- (N-METHYL-OR N, N-DIMETHYL) - 4-PHENYL-4`, 9`-DIHYDRO-3`H-SPIRO [CYCLOHEXANE-1,1`-PIRANO [3,4, B] INDOL] -4-AMINE | |
NZ600583A (en) | Visfatin therapeutic agents for the treatment of acne and other conditions | |
BR112015025804A2 (pt) | derivados de glutarimida, uso dos mesmos, composição farmacêutica com base neles e métodos para a produção de derivados de glutarimida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/05/2012, OBSERVADAS AS CONDICOES LEGAIS. |